Heart Test Laboratories (NASDAQ:HSCS) Trading Up 2.3% – Here’s Why

Heart Test Laboratories, Inc. (NASDAQ:HSCS) was up 2.3% during mid-day trading on Friday . The stock traded as high as $4.16 and last traded at $3.96. Approximately 31,324 shares were traded during trading, a decline of 74% from the average daily volume of 122,431 shares. The stock had previously closed at $3.87.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets dropped their price objective on Heart Test Laboratories from $15.00 to $14.00 and set a “buy” rating for the company in a report on Tuesday, March 18th.

Heart Test Laboratories Price Performance

The stock has a market capitalization of $4.28 million, a P/E ratio of -0.50 and a beta of 2.61. The company has a current ratio of 1.72, a quick ratio of 1.52 and a debt-to-equity ratio of 0.01. The company has a fifty day simple moving average of $3.27 and a two-hundred day simple moving average of $3.36.

Heart Test Laboratories (NASDAQ:HSCS) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($2.57) earnings per share for the quarter, missing the consensus estimate of ($2.53) by ($0.04). Sell-side analysts expect that Heart Test Laboratories, Inc. will post -10.01 EPS for the current fiscal year.

Institutional Trading of Heart Test Laboratories

A hedge fund recently bought a new stake in Heart Test Laboratories stock. Astoria Strategic Wealth Inc. purchased a new stake in Heart Test Laboratories, Inc. (NASDAQ:HSCS) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 18,927 shares of the company’s stock, valued at approximately $53,000. Astoria Strategic Wealth Inc. owned about 1.75% of Heart Test Laboratories at the end of the most recent reporting period. 17.24% of the stock is currently owned by institutional investors.

About Heart Test Laboratories

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.